| Source HCPCS Code |
|
Target NDC Code |
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00338-0063-01
DOXIL (STEALTH LIPOSOME, SDV) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2019 |
| Relationship End Date |
12/31/2025 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00338-0067-01
DOXIL (STEALTH LIPOSOME) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2019 |
| Relationship End Date |
12/31/2025 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00338-0080-01
DOXORUBICIN HCL (STEALTH LIPOSOME, SDV) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2019 |
| Relationship End Date |
02/28/2022 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00338-0086-01
DOXORUBICIN HCL (STEALTH LIPOSOME, SDV) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/01/2019 |
| Relationship End Date |
03/31/2022 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00338-9665-01
DOXIL STEALTH LIPOSOME, SDV 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
04/15/2025 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00338-9667-01
DOXIL STEALTH LIPOSOME, SDV 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
04/15/2025 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00574-0930-10
DOXORUBICIN HCL LIPOSOME (SDV,PF,LATEX-FREE) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/13/2021 |
| Relationship End Date |
04/30/2024 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
00574-0931-25
DOXORUBICIN HCL LIPOSOME (SDV,PF,LATEX-FREE) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/13/2021 |
| Relationship End Date |
04/30/2024 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
16714-0742-01
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/04/2017 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
16714-0856-01
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
10/04/2017 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
|
⇄
|
17314-9600-01
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
|
⇄
|
17314-9600-02
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
|
⇄
|
43598-0283-35
DOXORUBICIN LIPOSOME 20 MG/10 ML
|
| Detail Information |
| Relationship Start Date |
01/01/2025 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
|
⇄
|
43598-0541-25
DOXORUBICIN LIPOSOME 50 MG/25 ML
|
| Detail Information |
| Relationship Start Date |
01/01/2025 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
43598-0682-35
DOXORUBICIN HCL LIPOSOME NOVAPLUS 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
03/26/2018 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
43598-0683-25
DOXORUBICIN HCL LIPOSOME NOVAPLUS 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
03/26/2018 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
|
⇄
|
47335-0049-40
DOXORUBICIN LIPOSOME 20 MG/10 ML
|
| Detail Information |
| Relationship Start Date |
01/01/2025 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
|
⇄
|
47335-0050-40
DOXORUBICIN LIPOSOME 50 MG/25 ML
|
| Detail Information |
| Relationship Start Date |
01/01/2025 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
|
⇄
|
59676-0960-01
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
|
⇄
|
59676-0960-02
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
59676-0966-01
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
07/24/2017 |
| Relationship End Date |
09/30/2020 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
59676-0966-02
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
08/28/2017 |
| Relationship End Date |
10/31/2020 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
68001-0345-26
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
04/02/2018 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
68001-0345-36
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
04/02/2018 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
68001-0492-36
DOXORUBICIN HCL LIPOSOME (1X10ML;SD,LATEX-FREE) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
07/12/2021 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
68001-0493-26
DOXORUBICIN HCL LIPOSOME (1X25ML;SD,LATEX-FREE) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
07/12/2021 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
68001-0629-26
DOXORUBICIN HCL LIPOSOME 1X25ML;SDV 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
12/16/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
68001-0629-36
DOXORUBICIN HCL LIPOSOME 1X10ML;SDV 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
12/16/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
70710-1530-01
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
09/29/2020 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
70710-1531-01
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
09/29/2020 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
70748-0339-01
DOXORUBICIN HCL LIPOSOME (SDV) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
08/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
70748-0340-01
DOXORUBICIN HCL LIPOSOME (SDV) 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
08/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
72603-0103-01
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
07/17/2019 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
72603-0200-01
DOXORUBICIN HCL LIPOSOME 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
07/17/2019 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
72603-0346-01
DOXORUBICIN HCL LIPOSOME 1X10ML;SDV 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
06/16/2025 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
72603-0507-01
DOXORUBICIN HCL LIPOSOME 1X25ML;SDV 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
06/16/2025 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
75907-0363-01
DOXOrubicin HCl Liposome 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
01/29/2026 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
10 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG
|
⇄
|
75907-0364-01
DOXOrubicin HCl Liposome 2 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
01/29/2026 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
25 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VL |
| Route Of Administration |
IV |
| Billing Units |
ML |
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
00338-0063-01
Doxil
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
00338-0067-01
Doxil
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
00338-9665-01
Doxil
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
00338-9667-01
Doxil
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
68001-0345-26
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
68001-0345-36
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
68001-0492-36
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
68001-0493-26
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
68001-0629-26
Doxorubicin HCl Liposome
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
68001-0629-36
Doxorubicin HCl Liposome
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
43598-0283-35
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
43598-0541-25
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
43598-0682-35
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
43598-0683-25
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
70748-0339-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
70748-0340-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
16714-0742-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
16714-0856-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
72603-0103-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
72603-0200-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
47335-0049-40
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
47335-0050-40
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
70710-1530-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
Q2050
Doxorubicin inj 10mg
|
⇄
|
70710-1531-01
Doxorubicin HCl, Liposomal
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|